This article has been updated with a comment from PDI.

NEW YORK (GenomeWeb) – Prolias Technologies today said it has filed a lawsuit against PDI alleging breach of contract, breach of covenant of good faith and fair dealing, intentional interference with contract, and breach of fiduciary duty.  

Prolias, a New York-based molecular diagnostics firm, filed its lawsuit in Superior Court of New Jersey for the County of Morris. 

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

The US Food and Drug Administration has new guidelines that enable some gene and cell therapies to undergo expedited review, according to the New York Times.

Using gene drives to control invasive species might be too risky, an initial advocate of the approach says.

Researchers have grown tumors in 3D cell cultures to better understand cancer, the Economist reports.

In Science this week: intellectual property experts argue patent battles such as the one over CRISPR are wasteful, and more.